This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Fat embolization is common after long bone fractures. Presentations range from asymptomatic to the potentially fatal fat embolism syndrome (FES), a clinical triad of respiratory distress, neurologic changes, and a petechial rash.1 FES is not a well-recognized complication in Duchenne muscular dystrophy (DMD). We report 8 patients with DMD with FES after low-energy trauma, and discuss presenting features unique to this patient population.
Footnotes
Supplemental data at www.neurology.org
Author contributions: Dr. Medeiros: acquisition of data, analysis and interpretation, writing draft manuscript. Dr. Berhand: acquisition of data, analysis and interpretation. Wendy King: acquisition of data, critical revision of the manuscript for important intellectual content. Dr. Sanders: study concept and design, critical revision of the manuscript for important intellectual content. Dr. Kissel: study concept and design, critical revision of the manuscript for important intellectual content. Dr. Ciafaloni: study concept and design, critical revision of the manuscript for important intellectual content, study supervision.
Study funding: No targeted funding reported.
Disclosure: M. Medeiros, C. Behrend, and W. King report no disclosures. J. Sanders owns some stock in Abbot Labs, GE, Hospira, and Biomedical Enterprises, Inc. J. Kissel received drugs from Abbott Pharmaceuticals for a clinical trial in SMA, is a paid consultant for Alexion Pharmaceuticals and Cytokinetics, and is funded by NIH grant U10 NS77382-2 for NeuroNEXT. E. Ciafaloni is a paid consultant for the CDC. Go to Neurology.org for full disclosures.
- Received July 2, 2012.
- Accepted November 29, 2012.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Topics Discussed
Alert Me
Recommended articles
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study
Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1